WELCOME TO THE PASCOAL LAB
Our lab is interested in the quantification of brain pathophysiology in patients with Alzheimer’s disease (AD) and related dementias as well as in the validation of therapies capable of modifying the course of these diseases producing an enduring disease-modifying and clinically relevant effect. This involves the validation of positron emission tomography (PET) and fluid biomarker techniques capable of measuring these brain pathologies and monitoring their progression.
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults
Subjective cognitive decline in Brazil: Prevalence and association with dementia modifiable risk factors in a population-based study